Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
KNSA 
Kiniksa Pharmaceuticals Ltd (KNSA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: KNSA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $46.5
1 Year Target Price $46.5
| 4 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -33.42% | Avg. Invested days 29 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.48B USD | Price to earnings Ratio 669.8 | 1Y Target Price 46.5 |
Price to earnings Ratio 669.8 | 1Y Target Price 46.5 | ||
Volume (30-day avg) 6 | Beta 0.13 | 52 Weeks Range 17.82 - 34.55 | Updated Date 08/29/2025 |
52 Weeks Range 17.82 - 34.55 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.05 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 0.9% | Operating Margin (TTM) 12.86% |
Management Effectiveness
Return on Assets (TTM) 0.47% | Return on Equity (TTM) 1.03% |
Valuation
Trailing PE 669.8 | Forward PE - | Enterprise Value 2184589878 | Price to Sales(TTM) 4.69 |
Enterprise Value 2184589878 | Price to Sales(TTM) 4.69 | ||
Enterprise Value to Revenue 4.13 | Enterprise Value to EBITDA 365.5 | Shares Outstanding 43472900 | Shares Floating 33561881 |
Shares Outstanding 43472900 | Shares Floating 33561881 | ||
Percent Insiders 3.68 | Percent Institutions 93.03 |
Upturn AI SWOT
Kiniksa Pharmaceuticals Ltd
Company Overview
History and Background
Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients with significant unmet medical need. It was founded in 2015. They focus on therapies for autoinflammatory and autoimmune diseases.
Core Business Areas
- Therapeutic Development: Focuses on developing therapies for autoinflammatory and autoimmune diseases.
- Commercialization: Involves the marketing and sales of approved therapies.
- Research and Discovery: Dedicated to identifying and researching new potential therapies.
Leadership and Structure
The leadership team comprises experienced executives in the pharmaceutical industry. The organizational structure is typical of a biopharmaceutical company, with distinct departments for research, development, commercial operations, and administration. Sanj Patel is the current Chief Executive Officer.
Top Products and Market Share
Key Offerings
- Mavrilimumab (Mav):: A monoclonal antibody targeting GM-CSF receptor alpha, in development for Giant Cell Arteritis (GCA). There is currently no market share data available as it is in the developing phase. Competitors include Roche (Actemra) and Sanofi (Kevzara), which target IL-6 receptors.
- Arcalyst (rilonacept): An interleukin-1alpha (IL-1u03b1) trap indicated for recurrent pericarditis and other autoinflammatory conditions. Competitors in the autoinflammatory space include Novartis (Ilaris) and Regeneron (Arcalyst).
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. Demand for novel therapies for autoimmune and inflammatory diseases remains strong.
Positioning
Kiniksa Pharmaceuticals is positioning itself as a leader in the development of therapies for autoinflammatory and autoimmune diseases. They focus on areas with significant unmet medical needs.
Total Addressable Market (TAM)
The TAM for autoinflammatory and autoimmune disease therapies is estimated to be in the billions of dollars. Kiniksa is positioned to capture a portion of this market with its pipeline of products.
Upturn SWOT Analysis
Strengths
- Strong pipeline of product candidates
- Experienced management team
- Focus on areas of unmet medical need
- Arcalyst approved and marketed
Weaknesses
- Dependence on key products
- High research and development costs
- Reliance on successful clinical trial outcomes
- Limited Market Share
Opportunities
- Expansion into new therapeutic areas
- Potential for partnerships and collaborations
- Successful commercialization of pipeline products
- FDA approval for Mavrilimumab
Threats
- Competition from other pharmaceutical companies
- Regulatory hurdles
- Unsuccessful clinical trial outcomes
- Patent expirations
Competitors and Market Share
Key Competitors
- NVS
- SNY
- REGN
Competitive Landscape
Kiniksa faces competition from larger pharmaceutical companies with established products and greater resources. However, it also has the advantage of a focused pipeline and innovative therapies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is tied to the success of Arcalyst and the progress of its pipeline. Recent growth initiatives will be explained below.
Future Projections: Future growth is dependent on the successful development and commercialization of pipeline products.
Recent Initiatives: Recent initiatives include clinical trials for Mavrilimumab and expanding indications for Arcalyst. They also focus on securing partnerships and collaborations to advance their pipeline.
Summary
Kiniksa Pharmaceuticals is a biopharmaceutical company focused on autoinflammatory and autoimmune diseases. They have a promising pipeline, but are still relatively small. The company's success hinges on the successful development and commercialization of its pipeline products, facing competition from larger players. They need to prove their drug Mavrilimumab has positive trial results to secure more partnerships and FDA approval. Kiniksa's success will be determined by clinical outcomes and market adoption.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Kiniksa Pharmaceuticals Ltd. Investor Relations
- SEC Filings
- Industry Reports
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market data and financial information are subject to change. This analysis uses publicly available information and AI-assisted interpretation.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Kiniksa Pharmaceuticals Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2018-05-24 | CEO & Chairman of the Board Mr. Sanj K. Patel | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 315 | Website https://www.kiniksa.com |
Full time employees 315 | Website https://www.kiniksa.com | ||
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, developing and commercializing novel therapies for diseases with unmet need and focuses on cardiovascular indications worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-387, an investigational, that is in Phase 2/3 clinical trial for human immunoglobulin G2 monoclonal antibody that binds human interleukin-1 receptor 1, inhibiting IL-1a, IL-1ß-mediated signaling for the treatment of advance recurrent pericarditis by providing the added convenience of monthly subcutaneous dosing with a liquid formulation. Its preclinical products include KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody. The company was formerly known as Kiniksa Pharmaceuticals, Ltd and changed its name tpKiniksa Pharmaceuticals International, plc in June 2024. The company was incorporated in 2015 and is based in London, the United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.